Expression of GLUT‐1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F‐18]‐fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary
暂无分享,去创建一个
Y. Yonekura | Y. Fujibayashi | T. Tsuchida | H. Okazawa | K. Kawahara | Y. Yoshida | T. Kurokawa | F. Kotsuji
[1] Peter Bartenstein,et al. Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma , 2003, Cancer.
[2] Y. Yonekura,et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range , 2002, Annals of nuclear medicine.
[3] K. Miura,et al. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. , 2002, Anticancer research.
[4] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[5] Torsten Mattfeldt,et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[6] D. Burstein,et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia , 2002, Cancer.
[7] T. Saga,et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] Paul J. van Diest,et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .
[9] R. Angioli,et al. GLUT‐1 expression in ovarian carcinoma , 2001, Cancer.
[10] T. Sugino,et al. Expression of glucose transporter‐1 in human gastric carcinoma , 2001, Cancer.
[11] R. Airley,et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] Y. Yoshida,et al. Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma. , 2000, Human pathology.
[13] D. Wood,et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] C. Gomez-Fernandez,et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. , 2000, Gynecologic oncology.
[15] D. Henry,et al. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. , 2000, Surgery.
[16] A. Folpe,et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] S. Franceschi,et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma , 2000, Cancer.
[18] N. Sadato,et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] D. Burstein,et al. GLUT1 glucose transporter expression in colorectal carcinoma , 1998, Cancer.
[20] T. A. Smith,et al. FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.
[21] H. Minn,et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] Mark A. Stephenson,et al. Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.
[23] G. Viale,et al. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Karl Brand,et al. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] David J. Yang,et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] H. Wilke,et al. Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction. , 1996, The New England journal of medicine.
[27] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.
[28] R L Wahl,et al. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] A. Ciavattini,et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: Index of proliferative activity with prognostic significance , 1995, Gynecologic oncology.
[30] K. Hubner,et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). , 1993, Gynecologic oncology.
[31] D. Weinberg,et al. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. , 1992, The American journal of pathology.
[32] E. Yordan,et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Melton,et al. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. , 1984, American journal of obstetrics and gynecology.
[34] P. V. van Diest,et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] K. Ulm,et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. , 2001, Cancer.
[36] S. Silverberg. Toward the development of a universal grading system for ovarian epithelial carcinoma. , 1999, Gynecologic oncology.
[37] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.